Regent Investment Management LLC Purchases 37,660 Shares of Horizon Pharma PLC (HZNP)

Regent Investment Management LLC grew its position in shares of Horizon Pharma PLC (NASDAQ:HZNP) by 71.7% in the 1st quarter, HoldingsChannel reports. The firm owned 90,150 shares of the biopharmaceutical company’s stock after buying an additional 37,660 shares during the period. Regent Investment Management LLC’s holdings in Horizon Pharma were worth $2,383,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Private Capital Group LLC increased its holdings in shares of Horizon Pharma by 141.5% during the 4th quarter. Private Capital Group LLC now owns 1,963 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,150 shares in the last quarter. Rehmann Capital Advisory Group increased its holdings in Horizon Pharma by 2,162.2% in the 3rd quarter. Rehmann Capital Advisory Group now owns 7,420 shares of the biopharmaceutical company’s stock worth $379,000 after acquiring an additional 7,092 shares in the last quarter. Nkcfo LLC purchased a new stake in Horizon Pharma in the 1st quarter worth $246,000. SG Americas Securities LLC increased its holdings in Horizon Pharma by 79.5% in the 4th quarter. SG Americas Securities LLC now owns 9,438 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 4,179 shares in the last quarter. Finally, Meeder Asset Management Inc. increased its holdings in Horizon Pharma by 631.9% in the 4th quarter. Meeder Asset Management Inc. now owns 9,947 shares of the biopharmaceutical company’s stock worth $194,000 after acquiring an additional 8,588 shares in the last quarter. 82.02% of the stock is owned by hedge funds and other institutional investors.

HZNP traded down $0.48 on Monday, hitting $24.44. 18,640 shares of the company’s stock were exchanged, compared to its average volume of 1,456,988. Horizon Pharma PLC has a fifty-two week low of $12.55 and a fifty-two week high of $29.44. The company has a quick ratio of 1.97, a current ratio of 2.03 and a debt-to-equity ratio of 1.80. The stock has a market cap of $4.57 billion, a PE ratio of 13.35, a price-to-earnings-growth ratio of 1.42 and a beta of 1.14.

Horizon Pharma (NASDAQ:HZNP) last announced its earnings results on Wednesday, February 27th. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.54 by $0.13. Horizon Pharma had a negative net margin of 6.34% and a positive return on equity of 34.09%. The company had revenue of $355.50 million for the quarter, compared to analysts’ expectations of $334.22 million. During the same quarter in the previous year, the company posted $0.29 EPS. The firm’s quarterly revenue was up 29.6% on a year-over-year basis. As a group, research analysts anticipate that Horizon Pharma PLC will post 1.7 earnings per share for the current year.

Several brokerages recently commented on HZNP. BidaskClub lowered shares of Horizon Pharma from a “hold” rating to a “sell” rating in a report on Friday. Piper Jaffray Companies set a $33.00 price target on shares of Horizon Pharma and gave the stock a “buy” rating in a report on Thursday, April 4th. BMO Capital Markets boosted their price target on shares of Horizon Pharma to $29.00 and gave the stock a “market perform” rating in a report on Thursday, April 4th. They noted that the move was a valuation call. Cantor Fitzgerald boosted their price target on shares of Horizon Pharma from $26.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Finally, Morgan Stanley raised shares of Horizon Pharma from an “equal weight” rating to an “overweight” rating and set a $32.00 price target for the company in a report on Friday, March 8th. One research analyst has rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $30.73.

In other Horizon Pharma news, EVP Geoffrey M. Curtis sold 8,835 shares of Horizon Pharma stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $23.15, for a total transaction of $204,530.25. Following the sale, the executive vice president now owns 32,202 shares of the company’s stock, valued at approximately $745,476.30. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Geoffrey M. Curtis sold 10,080 shares of Horizon Pharma stock in a transaction on Monday, February 25th. The stock was sold at an average price of $21.21, for a total transaction of $213,796.80. Following the sale, the executive vice president now directly owns 35,367 shares in the company, valued at approximately $750,134.07. The disclosure for this sale can be found here. Insiders own 3.90% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.thelincolnianonline.com/2019/04/22/regent-investment-management-llc-purchases-37660-shares-of-horizon-pharma-plc-hznp.html.

About Horizon Pharma

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Featured Story: Insider Trading – What You Need to Know

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.